Veracyte Stock Performance
| VCYT Stock | USD 35.63 0.65 1.79% |
The entity has a beta of 1.23, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Veracyte will likely underperform. At this point, Veracyte has a negative expected return of -0.42%. Please make sure to validate Veracyte's value at risk, rate of daily change, as well as the relationship between the Rate Of Daily Change and relative strength index , to decide if Veracyte performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Veracyte has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in March 2026. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return (0.90) | Five Day Return 3.16 | Year To Date Return (14.41) | Ten Year Return 468.65 | All Time Return 173.81 |
1 | Disposition of 1106 shares by Jones Evan Fa of Veracyte at 50.2493 subject to Rule 16b-3 | 11/25/2025 |
2 | Disposition of 1278 shares by John Leite of Veracyte at 47.51 subject to Rule 16b-3 | 12/04/2025 |
3 | Disposition of 8537 shares by Rebecca Chambers of Veracyte at 46.6143 subject to Rule 16b-3 | 12/12/2025 |
4 | Disposition of 100 shares by Annie McGuire of Veracyte at 43.68 subject to Rule 16b-3 | 12/16/2025 |
5 | Morgan Stanley Initiates Coverage Of Veracyte, Inc. | 12/31/2025 |
6 | Is Veracytes 2026 Growth Guidance And New US Launches Altering The Investment Case For Veracyte | 01/15/2026 |
7 | QRG Capital Management Inc. Sells 106,926 Shares of Veracyte, Inc. VCYT | 01/21/2026 |
8 | Veracyte, Inc. Sees Analyst Support as Guggenheim Reaffirms Buy Rating | 01/22/2026 |
9 | Why Veracyte is poised to beat earnings estimates again - MSN | 01/27/2026 |
10 | Veracytes Growth Story Hit A Valuation Wall - Finimize | 02/02/2026 |
11 | Federated Hermes Inc. Sells 52,0 Shares of Veracyte, Inc. VCYT | 02/10/2026 |
12 | A Look At Veracyte Valuation After UBS Reiterates Positive View On Q4 Revenue Performance | 02/19/2026 |
| Begin Period Cash Flow | 217.3 M | |
| Total Cashflows From Investing Activities | -56.3 M |
Veracyte Relative Risk vs. Return Landscape
If you would invest 4,670 in Veracyte on November 22, 2025 and sell it today you would lose (1,107) from holding Veracyte or give up 23.7% of portfolio value over 90 days. Veracyte is currently does not generate positive expected returns and assumes 2.3771% risk (volatility on return distribution) over the 90 days horizon. In different words, 21% of stocks are less volatile than Veracyte, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Veracyte Target Price Odds to finish over Current Price
The tendency of Veracyte Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 35.63 | 90 days | 35.63 | over 95.63 |
Based on a normal probability distribution, the odds of Veracyte to move above the current price in 90 days from now is over 95.63 (This Veracyte probability density function shows the probability of Veracyte Stock to fall within a particular range of prices over 90 days) .
Veracyte Price Density |
| Price |
Predictive Modules for Veracyte
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Veracyte. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Veracyte's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Veracyte Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Veracyte is not an exception. The market had few large corrections towards the Veracyte's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Veracyte, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Veracyte within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.18 | |
β | Beta against Dow Jones | 1.23 | |
σ | Overall volatility | 3.51 | |
Ir | Information ratio | -0.07 |
Veracyte Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Veracyte for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Veracyte can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Veracyte generated a negative expected return over the last 90 days | |
| Veracyte is unlikely to experience financial distress in the next 2 years | |
| Veracyte has a strong financial position based on the latest SEC filings | |
| Over 99.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from simplywall.st: A Look At Veracyte Valuation After UBS Reiterates Positive View On Q4 Revenue Performance |
Veracyte Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Veracyte Stock often depends not only on the future outlook of the current and potential Veracyte's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Veracyte's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 78.2 M | |
| Cash And Short Term Investments | 289.4 M |
Veracyte Fundamentals Growth
Veracyte Stock prices reflect investors' perceptions of the future prospects and financial health of Veracyte, and Veracyte fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Veracyte Stock performance.
| Return On Equity | 0.0249 | ||||
| Return On Asset | 0.0243 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 2.5 B | ||||
| Shares Outstanding | 79.05 M | ||||
| Price To Earning | (10.61) X | ||||
| Price To Book | 2.25 X | ||||
| Price To Sales | 5.79 X | ||||
| Revenue | 445.76 M | ||||
| Gross Profit | 349.6 M | ||||
| EBITDA | 49.2 M | ||||
| Net Income | 24.14 M | ||||
| Cash And Equivalents | 170.11 M | ||||
| Cash Per Share | 2.37 X | ||||
| Total Debt | 50.74 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 4.09 X | ||||
| Book Value Per Share | 15.91 X | ||||
| Cash Flow From Operations | 75.1 M | ||||
| Earnings Per Share | 0.38 X | ||||
| Market Capitalization | 2.87 B | ||||
| Total Asset | 1.3 B | ||||
| Retained Earnings | (443.98 M) | ||||
| Working Capital | 293.63 M | ||||
| Current Asset | 47.91 M | ||||
| Current Liabilities | 14.72 M | ||||
About Veracyte Performance
Assessing Veracyte's fundamental ratios provides investors with valuable insights into Veracyte's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Veracyte is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 61.85 | 61.48 | |
| Return On Tangible Assets | 0.05 | 0.05 | |
| Return On Capital Employed | 0.01 | 0.01 | |
| Return On Assets | 0.02 | 0.02 | |
| Return On Equity | 0.02 | 0.02 |
Things to note about Veracyte performance evaluation
Checking the ongoing alerts about Veracyte for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Veracyte help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Veracyte generated a negative expected return over the last 90 days | |
| Veracyte is unlikely to experience financial distress in the next 2 years | |
| Veracyte has a strong financial position based on the latest SEC filings | |
| Over 99.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from simplywall.st: A Look At Veracyte Valuation After UBS Reiterates Positive View On Q4 Revenue Performance |
- Analyzing Veracyte's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Veracyte's stock is overvalued or undervalued compared to its peers.
- Examining Veracyte's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Veracyte's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Veracyte's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Veracyte's stock. These opinions can provide insight into Veracyte's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Veracyte Stock Analysis
When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.